Pharma BD Deal Intelligence
Zydus won a bidding war, topping Garda Therapeutics' $21.80/share with $23.50/share cash — a 7.8% premium worth roughly $166.4M — to grab Assertio's Rolvedon-anchored specialty portfolio, though it had to absorb Garda's termination fee to close the deal.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Cosette Pharmaceuticals announced the acquisition of the SYMPAZAN, INDOCIN, SPRIX, CAMBIA, ZIPSOR and OTREXUP product franchises from Assertio Holdings for an…
Zydus Lifesciences Limited announced that its subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Assertio…
Assertio Holdings filed a Form 8-K announcing entry into an Agreement and Plan of Merger with Zydus Worldwide DMCC and Zoom Merger Sub Inc. providing for the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Zydus Worldwide DMCC (subsidiary of Zydus Lifesciences) entered a definitive agreement to acquire Assertio Holdings for $23.50/share cash, total consideration ~$166.4M, after Assertio's board deemed Zydus's bid a Superior Proposal over Garda Therapeutics' competing $21.80/share offer (Garda agreement terminated). Adds Assertio's US specialty/oncology supportive-care portfolio (Indocin, Sympazan, Otrexup, Sympan, Rolvedon).
60K US cases/yr · $2.5B 2024 US long-acting G-CSF market, IQVIA (Neulasta franchise + biosimilars + Udenyca + Rolvedon) · $48.9M Assertio 2025 specialty product net sales (Indocin/Sympazan/Sprix/Otrexup/Cambia/Zipsor) divested to Cosette April 2026
Febrile neutropenia is a life-threatening complication of myelosuppressive chemotherapy, defined by absolute neutrophil count <500/uL plus fever. Long-acting G-CSFs (pegfilgrastim, eflapegrastim) reduce duration of severe neutropenia and FN incidence. Unmet need is driven by reactogenicity, biosimilar pricing pressure on pegfilgrastim, and demand for same-day dosing to eliminate the need for next-day clinic returns.
Rolvedon competes against Amgen's Neulasta and Onpro device, plus pegfilgrastim biosimilars from Coherus (Udenyca), Sandoz (Ziextenzo), Pfizer (Nyvepria), Teva (Fulphila), Apotex (Lapelga) and Spectrum's legacy distributors. Same-day dosing data positions Rolvedon against next-day dosing requirement of Neulasta. Zydus inherits a fragmented, biosimilar-eroded supportive-care franchise with the bulk of Assertio's branded portfolio already sold to Cosette for $35M upfront.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Zydus Lifesciences Limited / Assertio Holdings, Inc. (this deal) | 2026 | $166M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals